Coriolis Pharma opens new US headquarter and laboratory
Lucy Batizovsky | March 16, 2026 | News story | Manufacturing and Production | Coriolis Pharma, US, development
Coriolis Pharma has opened a new US headquarter and laboratory at the Alexandria Center for Advanced Technologies (ACAT) in North Carolina’s Research Triangle Park (RTP).
Coriolis’ US clients will now have direct access to specialised expertise in formulation and drug product development through the three core services offered at the new site.
The new site offers particle analysis and fast track analytics, formulation development and drug product development. These services will be rolled out progressively throughout the year, with all being available by Q4 2026.
Silvia Steyrer Gruber, CEO of Coriolis Pharma said: “Opening our lab and US headquarters in North Carolina is a major leap forward for Coriolis. It fuels our mission to empower innovation where it happens.
“The region’s scientific excellence, cutting edge biotech and manufacturing ecosystem and collaborative energy make it the perfect home for our next chapter.”
Any services offered through the new site will be provided through collaboration with experts at the German headquarters and their global partners, meaning clients will be provided with end-to-end solutions from a single point of contact.
John Gabrielson, President of Coriolis Pharma US, said: “We are excited to bring our deep scientific expertise and comprehensive service offerings to the vibrant life science community in North Carolina.
“Together with our colleagues in Germany and partners worldwide, we will deliver solutions that meet the highest quality standards – empowering companies in the US to accelerate their development programmes and drive innovation forward.”
Coriolis Pharma supports global pharmaceutical and biotech partners with expert drug product development services.
Related Content
Abselion establishes a US subsidiary in Massachusetts
Abselion has established a US subsidiary at The Engine in Cambridge, Massachusetts in the US. …
ESTEVE CDMO commences $15.5m expansion of US facility
ESTEVE CDMO, a global Contract Development and Manufacturing Organization (CDMO) specialising in small molecule active pharmaceutical …
Sharp invests $100m in US and EU manufacturing and packaging facilities
Sharp Services, a pharmaceutical packaging and sterile manufacturing specialist, has announced investments totalling $100m across …
